Benjamin Castleman Professor of Pathology at Harvard Medical School, Pathologist-in-Chief at Massachusetts General Hospital, and Leader of the Mass General Brigham Enterprise Laboratory Service
David N. Louis, MD, is the Benjamin Castleman Professor of Pathology at Harvard Medical School, Pathologist-in-Chief at Massachusetts General Hospital, and leader of the Mass General Brigham Enterprise Laboratory Service. Pathology at MGH has nearly 100 faculty members, over 100 trainees and over 700 employees, and performs about 15 million laboratory tests as well as 90,000 surgical pathology evaluations, 500,000 microbiology analyses, and 50,000 cytologies each year. Under Dr. Louis’ chairmanship, the department has become a national leader in molecular diagnostics and pathology informatics, leading to a novel initiative in computational pathology. Dr. Louis' own clinical neuropathology practice and research focuses on brain tumors, with an emphasis on the molecular basis of malignant gliomas and the application of molecular diagnostics to glioma classification. He has published about 300 original articles, as well as numerous reviews, chapters and books (h-index = 113). His laboratory was the first to demonstrate that molecular approaches could be used to subdivide malignant gliomas in a biologically relevant manner and that molecular approaches could be used to predict the response of particular malignant gliomas to specific therapies. This work has contributed to worldwide adoption of molecular testing for the management of patients with these tumors. Dr. Louis has received prestigious awards for his work, including the 2008 International Prize for Translational Neuroscience of the Max Planck Society and both the Farber Award and the Victor Levin Award for Neuro-Oncology Research from the Society for Neuro-Oncology. Dr. Louis served on the 2000 WHO Committee on the Classification of Tumours of Nervous System; he also co-chaired and was the primary editor for both the 2007 and 2016 WHO Classification of Tumours of the Central Nervous System and is a leading member of the expert panel for the 2021 WHO Classification of Tumours of the Central Nervous System. Dr. Louis chaired the CNS tumor committee for the International Collaboration on Cancer Reporting and is the founder and inaugural Steering Committee chair for cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy). He has served as chair of the Scientific Advisory Panel of the Brain Tumor Society, on the Board of Directors of the Society for Neuro-Oncology, and on editorial boards of more than 10 national and international journals. At the American Association of Neuropathologists, he has served as President in 2009-10 and gave the invited Saul Korey Lecture in 2008 and Matthew Moore Lecture in 2014, among many other talks. Dr. Louis was one of three editors for the 8th edition of Greenfield's Neuropathology, the standard international reference in neuropathology, and is first author of the Armed Forces Institute of Pathology Fascicle on Non-Neoplastic Diseases of the Central Nervous System. He was also co-chair of the Brain Tumor Progress Review Group sponsored by the NIH and was the founding chair of the Cancer Biomarkers Study Section at NIH. Dr. Louis served as chair of the Harvard Medical School Pathology Executive Committee, which governs the department of Pathology at Harvard Medical School and was recently chair of the MGH Executive Committee on Research, which oversaw the approximately $900M research enterprise at MGH. He has facilitated a number of joint activities between MGH and MIT, including co-chairing the MGH-MIT Grand Challenge in Diagnostics between 2013 and 2019. Given his expertise in computational diagnostics, Dr. Louis is currently Executive Sponsor of the MGH Center for Innovation in Digital Health. Dr. Louis is also interested in medical history and has published articles on the history of pathology and a book on the history of the pathology services at the Massachusetts General Hospital.
Professor of Pathology and Oncology, CA. Wilson and MK. Whitener Professor of Ophthalmology at Johns Hopkins University School of Medicine
Dr. Charles Eberhart received his M.D. and Ph.D. degrees from UT Southwestern in 1997, with post-graduate clinical training in Anatomical Pathology and Neuropathology at Johns Hopkins Hospital. Dr. Eberhart has been a member of the Johns Hopkins University School of Medicine faculty since 2001, and directs the divisions of Neuropathology and Ophthalmic Pathology. He works as both a diagnostic pathologist and a scientist studying how brain and eye diseases can be better classified and treated. Dr. Eberhart is a member of numerous organizations, and is on the editorial boards of the Journal of Neuropathology and Experimental Neurology, Neuro-oncology, Journal of Neuro-Ophthalmology (Neuropathology Consultant) and Brain Pathology. He authored multiple chapters in the 4th edition (initial and revision) and 5th edition of the 2021 World Health Organization (WHO) CNS Tumor Classifications, was one of three senior editors of the WHO Ocular Tumor Classification 4th edition, and is on the editorial board of the upcoming WHO Ocular Tumor Classification 5th edition. Dr. Eberhart has published over 340 original research articles on diseases of the brain and eye, along with numerous case reports, book chapters and reviews.